Company Description
Cardiff Oncology, Inc., a clinical-stage biotechnology company, develops novel therapies to treat various cancers in California.
Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor to treatment a range of solid tumor cancers and KRAS/NRAS-mutated metastatic colorectal and metastatic pancreatic cancer, as well as investigator-initiated trials in triple negative breast cancer and small cell lung cancer; and TROV-054 is a Phase 1b/2 for FOLFIRI and bevacizumab.
The company primarily serves pharmaceutical manufacturers. The company was formerly known as Trovagene, Inc. and changed its name to Cardiff Oncology, Inc. in May 2012.
Cardiff Oncology, Inc. was incorporated in 1999 and is headquartered in San Diego, California.
| Country | United States |
| Founded | 1999 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 32 |
| CEO | Dr. Mark Erlander Ph.D. |
Contact Details
Address: 11055 Flintkote Avenue San Diego, California 92121 United States | |
| Phone | 858-952-7570 |
| Website | cardiffoncology.com |
Stock Details
| Ticker Symbol | CRDF |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001213037 |
| CUSIP Number | 14147L108 |
| ISIN Number | US14147L1089 |
| Employer ID | 27-2004382 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. Mark Erlander Ph.D. | Chief Executive Officer and Director |
| James E. Levine | Chief Financial Officer |
| Dr. Tod Smeal Ph.D. | Chief Scientific Officer? |
| Elizabeth Anderson | Vice President of Finance and Administration |
| Brigitte Lindsay | Senior Vice President of Finance |
| Charles Monahan R.Ph. | Senior Vice President of Regulatory Affairs |
| Dr. Fairooz Kabbinavar FACP, M.D. | Chief Medical Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jul 1, 2024 | S-8 | Securities to be offered to employees in employee benefit plans |
| Jun 20, 2024 | 8-K | Current Report |
| Jun 17, 2024 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Jun 3, 2024 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Jun 3, 2024 | 8-K | Current Report |
| May 2, 2024 | 8-K | Current Report |
| May 2, 2024 | 10-Q | Quarterly Report |
| Apr 25, 2024 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 25, 2024 | ARS | Filing |
| Apr 25, 2024 | DEF 14A | Other definitive proxy statements |